Caspase-independent hepatocyte death: A result of the decrease of lysophosphatidylcholine acyltransferase 3 in non-alcoholic steatohepatitis.


Journal

Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 04 06 2018
revised: 17 08 2018
accepted: 24 08 2018
pubmed: 31 8 2018
medline: 30 1 2020
entrez: 31 8 2018
Statut: ppublish

Résumé

Lipotoxicity causes liver inflammation, which leads to non-alcoholic steatohepatitis (NASH). Lysophosphatidylcholine (LPC) is a causal agent of lipotoxicity. Recently, lysophosphatidylcholine acyltransferase (LPCAT) was identified as an enzyme that catalyzes the esterification of LPC, which potentially decreases LPC levels. However, the effect of LPCAT in lipotoxicity of the liver is not fully understood. Our aim was to determine whether LPCAT attenuates lipotoxicity in the liver. Mice fed a high-fat diet with sucrose (HFDS) or high-fat diet without sucrose, and Huh-7 cells treated with palmitate were used. Mice-fed HFDS showed advanced liver fibrosis as compared with mice-fed high-fat diet or normal chow. Lysophosphatidylcholine acyltransferase 3 (LPCAT3) mRNA expression in the liver was significantly decreased in the HFDS liver, and LPC content in the HFDS liver was significantly increased as compared with the other groups. When Huh-7 cells with short hairpin RNA-mediated knockdown of LPCAT3 (shLPCAT3 cells) were treated with palmitate, the intracellular LPC concentration and cell death were significantly higher than those in wild-type Huh-7 cells. Palmitate-induced cell death in shLPCAT3 was attenuated by a combination of receptor-interacting protein kinase 1 inhibitor with pan-caspase inhibitor. In contrast, intracellular LPC and palmitate-induced cell death were significantly lower in LPCAT3-overexpressing Huh-7 cells than in wild-type cells. Depletion of LPCAT3 in a mouse model of NASH leads to caspase-independent cell death, and LPCAT3 is a potential therapeutic target in NASH.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Lipotoxicity causes liver inflammation, which leads to non-alcoholic steatohepatitis (NASH). Lysophosphatidylcholine (LPC) is a causal agent of lipotoxicity. Recently, lysophosphatidylcholine acyltransferase (LPCAT) was identified as an enzyme that catalyzes the esterification of LPC, which potentially decreases LPC levels. However, the effect of LPCAT in lipotoxicity of the liver is not fully understood. Our aim was to determine whether LPCAT attenuates lipotoxicity in the liver.
METHODS METHODS
Mice fed a high-fat diet with sucrose (HFDS) or high-fat diet without sucrose, and Huh-7 cells treated with palmitate were used.
RESULTS RESULTS
Mice-fed HFDS showed advanced liver fibrosis as compared with mice-fed high-fat diet or normal chow. Lysophosphatidylcholine acyltransferase 3 (LPCAT3) mRNA expression in the liver was significantly decreased in the HFDS liver, and LPC content in the HFDS liver was significantly increased as compared with the other groups. When Huh-7 cells with short hairpin RNA-mediated knockdown of LPCAT3 (shLPCAT3 cells) were treated with palmitate, the intracellular LPC concentration and cell death were significantly higher than those in wild-type Huh-7 cells. Palmitate-induced cell death in shLPCAT3 was attenuated by a combination of receptor-interacting protein kinase 1 inhibitor with pan-caspase inhibitor. In contrast, intracellular LPC and palmitate-induced cell death were significantly lower in LPCAT3-overexpressing Huh-7 cells than in wild-type cells.
CONCLUSION CONCLUSIONS
Depletion of LPCAT3 in a mouse model of NASH leads to caspase-independent cell death, and LPCAT3 is a potential therapeutic target in NASH.

Identifiants

pubmed: 30160786
doi: 10.1111/jgh.14461
doi:

Substances chimiques

Dietary Sucrose 0
Lysophosphatidylcholines 0
1-Acylglycerophosphocholine O-Acyltransferase EC 2.3.1.23
LPCAT3 protein, human EC 2.3.1.23
LPCAT3 protein, mouse EC 2.3.1.23
Caspases EC 3.4.22.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1256-1262

Subventions

Organisme : Daiichi Sankyo Co., Ltd.
Organisme : KAKENHI
ID : JP18K07980
Organisme : Grant-in-Aid for Scientific Research(C)
ID : JP18K07980

Informations de copyright

© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Auteurs

Keisuke Kakisaka (K)

Division of Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka, Japan.

Yuji Suzuki (Y)

Division of Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka, Japan.

Yudai Fujiwara (Y)

Division of Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka, Japan.

Akiko Suzuki (A)

Division of Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka, Japan.

Jo Kanazawa (J)

Division of Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka, Japan.

Yasuhiro Takikawa (Y)

Division of Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH